Division of Cardiology The Children's Hospital of Philadelphia Philadelphia PA.
Center for Pediatric Clinical Effectiveness The Children's Hospital of Philadelphia Philadelphia PA.
J Am Heart Assoc. 2022 Apr 5;11(7):e024197. doi: 10.1161/JAHA.121.024197. Epub 2022 Mar 18.
Background Universal lipid screening in children provides an opportunity to mitigate the lifetime risk of atherosclerosis, particularly in children with chronic conditions that are predisposed to early atherosclerosis. In response, national guidelines recommend additional early screening in a subset of cardiac conditions. The penetration of such guidelines has not been evaluated. Methods and Results We performed a retrospective study of a geographically representative sample of US children using the MarketScan Commercial and Medicaid claims databases. The study population was children with cardiac disease between ages 2 and 18 years and ≥3 years of continuous coverage from January 1, 2013, to June 30, 2018, divided into 4 major strata of heart disease. We assessed the likelihood of screening between these classifications and compared with healthy children and calculated multivariate models to identify patient factors associated with screening likelihood. Of the eligible 8.4 million children, 155 000 children had heart disease, of which 1.8% (31 216) had high-risk conditions. Only 17.5% of healthy children underwent lipid screening. High-risk children were more likely to be screened (odds ratio [OR], 2.1; 95% CI, 2.09-2.19; <0.001) than standard-risk children, but that likelihood varied depending on strata of cardiac disease (22%-77%). Timing of screening also varied, with most occurring between ages 9 and 11 years. Among cardiac conditions, heart transplantation (OR, 16.8; 95% CI, 14.4-19.7) and cardiomyopathy (OR, 2.9; 95% CI, 2.8-3.1) were associated with the highest likelihood of screening. Conclusions Children with cardiac disease are more likely to undergo recommended lipid screening than healthy children, but at lower rates and later ages than recommended, highlighting the importance of quality improvement and advocacy for this vulnerable population.
背景 对儿童进行普遍的血脂筛查为降低其终生罹患动脉粥样硬化的风险提供了机会,尤其是对于存在易患早期动脉粥样硬化的慢性疾病的儿童。为此,国家指南建议在部分心脏疾病中进行早期的额外筛查。但这些指南的渗透情况尚未得到评估。
方法和结果 我们使用市场扫描商业和医疗补助索赔数据库,对美国具有代表性的地理区域的儿童进行了回顾性研究。研究人群为年龄在 2 至 18 岁之间且在 2013 年 1 月 1 日至 2018 年 6 月 30 日期间有≥3 年连续覆盖范围的患有心脏病的儿童,并将其分为 4 大主要心脏病亚组。我们评估了这些分类之间进行筛查的可能性,并与健康儿童进行了比较,并建立了多变量模型以确定与筛查可能性相关的患者因素。在符合条件的 840 万儿童中,有 155000 名儿童患有心脏病,其中 1.8%(31216 名)患有高危疾病。只有 17.5%的健康儿童接受了血脂筛查。患有高危疾病的儿童更有可能接受筛查(比值比[OR],2.1;95%CI,2.09-2.19;<0.001),但这种可能性取决于心脏病的亚组(22%-77%)。筛查的时间也有所不同,大多数发生在 9 至 11 岁之间。在心脏疾病中,心脏移植(OR,16.8;95%CI,14.4-19.7)和心肌病(OR,2.9;95%CI,2.8-3.1)与最高的筛查可能性相关。
结论 与健康儿童相比,患有心脏病的儿童更有可能接受推荐的血脂筛查,但筛查率和年龄均低于推荐水平,这突出了为这一弱势群体改善质量和宣传的重要性。